Clinical Diagnosis

The decision follows results from the Phase 3 STAR trial, among the largest global studies of low-dose atropine in pediatric myopia.

Innovations in surgery, biologics, and AI are shaping the future of eye aesthetics.

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.

Inder Paul Singh, MD, shares a formative experience in which a patient’s vision loss—and their unexpected gesture of comfort—shaped his approach to high-risk glaucoma care.

How pupil modulation and pharmacologic targeting shape near vision outcomes.

SriniVas R. Sadda, MD, FARVO, recalls a residency case that highlights the transformative impact of OCT and OCT angiography.

Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.

Phase 2 STARLIGHT study participants, particularly those with the macular phenotype, experienced meaningful gains in visual acuity at 48 weeks.

The incision-free therapeutic for keratoconus is expected to be commercially available in early 2026, according to the company.

Bedrood describes improved visualization of the ciliary body, efficient setup, and favorable postoperative outcomes.

Telemedicine, mobile clinics, and policy reform offer a road map to equitable care.

Innovations in selective laser trabeculoplasty and laser cyclophotocoagulation focus on procedural efficiency, patient comfort, and evolving first-line treatment strategies.

In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

NYU Grossman School of Medicine’s Galen Hu, MD, and Andrea Blitzer, MD, sit down with Eduardo C. Alfonso, MD, of Bascom Palmer Eye Institute, to discuss how ophthalmologists are leveraging social media not just to promote practices, but to educate patients.

Andrew G. Lee, MD, and Drew Carey, MD, highlight how chronic lymphocytic leukemia can mimic Graves’ orbitopathy, underscoring the importance of a thorough evaluation.

The approval of the third-generation trifocal intraocular lens broadens the range of advanced lens options available for patients in the US.

Emerging pharmacological and optical strategies are shaping a new era.

Singh highlights how understanding the “why” behind diagnostics and procedures boosts technician confidence, fosters pride, and strengthens their role in patient care.

The video-driven platform equips ophthalmic practices with tools to standardize education, improve workflow, and foster technician engagement.

A young surgeon reflects on training, technology, and the human side of adopting new excimer laser platforms.

Subramanian discusses how subtle retinal and optic nerve findings can point to underlying neurologic disease.

By letting patients “see” their options before surgery, virtual reality may eliminate confusion, boost confidence, and strengthen surgeon–patient trust.

By combining anatomical fidelity with reproducibility, NRSS offers a novel way to train surgeons, validate clinical trials, and expand access to advanced techniques worldwide.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

Immersive VR simulation helps patients better understand intraocular lens options.